Clinical Trial Update: A Study to Assess the Pharmacokinetics, Immunogenicity and Safety of Escalating Doses of BMS-188667 Given as a Single Intravenous Infusion to Patients With Psoriasis Vulgaris [Phase 1]

View source ↗

Summary

Phase 1 study assessing pharmacokinetics, immunogenicity, and safety of escalating intravenous doses of BMS-188667 in patients with psoriasis vulgaris; the tria…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis Vulgaris

Drugs mentioned

• BMS-188667

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Psoriasis Vulgaris | Phase 1 | Status: COMPLETED